- Home
- NTIP vs LTRN Comparison
NTIP vs LTRN Comparison
Compare NTIP & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | LTRN |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 27.6M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTIP | LTRN |
|---|---|---|
| Price | $1.57 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 17.3K | ★ 236.0K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 6.25% | N/A |
| EPS Growth | 15.38 | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.24 | $1.01 |
| 52 Week High | $1.75 | $4.70 |
Technical Indicators
Market Signals| Indicator | NTIP | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 18.64 |
| Support Level | $1.42 | N/A |
| Resistance Level | $1.66 | $1.96 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 64.12 | 4.12 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.